Anas Hamad: Thrombosis as Overlooked Clinical Challenge in APL
Anas Hamad, Deputy Chief of Drug Supply Department, Head of Pharmacy Research Center, Corporate Pharmacy Executive Office at Hamad Medical Corporation, Lead of Health Technology Assessment and Innovation Regulation National Program at Ministry of Public Health – Qatar, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Sage Journals, adding:
“I am pleased to share our recently published study in clinical and applied Thrombosis/Hemostasis Journal by Sage: ‘Beyond Bleeding: Underrecognized Thrombotic Complications in Acute Promyelocytic Leukemia — A Single-Center Experience from the GCC Region.’
APL is often recognized for its bleeding risk, but our study highlights another important and sometimes underrecognized clinical challenge: thrombosis.
In this work from the National Center for Cancer Care and Research in Qatar, we reviewed 75 consecutive patients with newly diagnosed APL treated between 2015 and 2024.
We found that 14.7 percent developed thrombosis, with most events occurring during active therapy.
Importantly, this study reinforces that managing APL requires careful attention to both sides of the coagulation spectrum: bleeding and thrombosis.
This balance is particularly critical during induction and early consolidation, where individualized thrombo-hemorrhagic assessment and multidisciplinary decision-making are essential.
Grateful to all the authors team for their great efforts and valuable contributions to this publication.”
Title: Beyond Bleeding: Underrecognized Thrombotic Complications in Acute Promyelocytic Leukemia — A Single-Center Experience from the GCC Region
Authors: Shehab F. Mohamed, Rafal AlShebly, Hawraa Shawaylia, Anil Elahie, Rola Ghasoub, Dina Soliman, Deen Mudawi, Mohammed Abdulgayoom, Abdulrahman F. Al-Mashdali, Marrita Rabadi, Hesham El-Sabah, Anas Hamad, Mohamed Yassin, Honar Cherif

Stay updated on all scientific advances with Hemostasis Today.
-
Oct 8, 2026, 03:20Sthanu Subramanian: Leukopenia in Sepsis A Marker of Severe Disease
-
Oct 7, 2026, 16:44Amor Salah: 2026 NCS/SCCM Guidelines for Managing Antithrombotic-Associated ICH
-
Oct 7, 2026, 16:04NETs in Thrombosis: From Mechanism to Therapeutic Target
-
Oct 7, 2026, 15:28Amir Samimi: Prognostic Value of Platelet Count in Resected HNSCC
-
Oct 7, 2026, 15:21Eloïse Laouenan: Bridging Immunity and Thrombosis in MVTE
-
Oct 7, 2026, 15:10Uthra Sundaram: Honouring Donors During International Plasma Awareness Week
-
Oct 7, 2026, 15:04Daniel Victor Ortigoza: Should Frail Older Patients With AF Switch From VKA to DOACs?
-
Oct 7, 2026, 14:53Susan Noone: Donor Turned Recipient Shares Lifesaving Transfusion Story
-
Oct 7, 2026, 14:49Aimee Burtenshaw: The Impact of the Infected Blood Inquiry on Hospital Transfusion Laboratories